MAOB and Parkinson disease: Subsequent studies in animal models of PD also demonstrated in vivo that pre-treatment with selegiline or rasagiline is capable to markedly attenuate the behavioural deficits arising from neurotoxic MPTP and 6-hydroxydopamine injections [64,65], thereby nourishing further hope that MAO-B inhibitors would also harbour disease-modifying capabilities in the clinical setting.